Qianzhou Lv

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Atrial Fibrillation

Percutaneous Coronary Intervention

Body Mass Index

St Elevation Myocardial Infarction

Top Venues

International journal of clinical pharmacy

Cardiovascular therapeutics

Reviews in cardiovascular medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Huamin Ding, Zi Wang, Jia Wang, Yao Yao, Chi Zhang, Houwen Lin, Yong Zhou, Zhi-Chun Gu, Qianzhou Lv, Xiaoye Li
Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation. Pharmaceutics 16 (8) (2024)
Yao Yao, Yanli Li, Qinchun Jin, Xiaoye Li, Xiaochun Zhang, Qianzhou Lv
Perioperative Treatment with Rivaroxaban and Dabigatran on Changes of Coagulation and Platelet Activation Biomarkers following Left Atrial Appendage Closure. Cardiovascular therapeutics 2024 (2024)
Huamin Ding, Zi Wang, Jia Wang, Yao Yao, Chi Zhang, Houwen Lin, Yong Zhou, Zhi-Chun Gu, Qianzhou Lv, Xiaoye Li
Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation. Pharmaceutics 16 (8) (2024)
Yao Yao, Yanli Li, Qinchun Jin, Xiaoye Li, Xiaochun Zhang, Qianzhou Lv
Perioperative Treatment with Rivaroxaban and Dabigatran on Changes of Coagulation and Platelet Activation Biomarkers following Left Atrial Appendage Closure. Cardiovascular therapeutics 2024 (2024)
Yao Yao, Xiaoye Li, Zi Wang, Shikun Xu, Qianzhou Lv
The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study. International journal of clinical pharmacy (2023)
Xiaoye Li, Qinchun Jin, Yao Yao, Xiaochun Zhang, Qianzhou Lv
Clinical Effectiveness and Safety Comparison between Reduced Rivaroxaban Dose and Dual Antiplatelet Therapy for Nonvalvular Atrial Fibrillation Patients Following Percutaneous Left Atrial Appendage Closure: A Prospective Observational Study. Reviews in cardiovascular medicine 24 (11) (2023)
Xiaoye Li, Zhichun Gu, Zi Wang, Qing Xu, Chunlai Ma, Qianzhou Lv
Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation. Cardiovascular drugs and therapy (2023)
Xiaoye Li, Qinchun Jin, Yao Yao, Xiaochun Zhang, Qianzhou Lv
Clinical Effectiveness and Safety Comparison between Reduced Rivaroxaban Dose and Dual Antiplatelet Therapy for Nonvalvular Atrial Fibrillation Patients Following Percutaneous Left Atrial Appendage Closure: A Prospective Observational Study. Reviews in cardiovascular medicine 24 (11) (2023)
Meixiang Yu, Zi Wang, Liuliu Zong, Qing Xu, Xiaoye Li, Qianzhou Lv
A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation. International journal of clinical pharmacy 44 (5) (2022)
Yao Yao, Chunlai Shao, Xiaoye Li, Zi Wang, Chengchun Zuo, Yan Yan, Qianzhou Lv
A Novel Biomarker Scoring System Alone or in Combination with the GRACE Score for the Prognostic Assessment in Non-ST-Elevation Myocardial Infarction. Clinical epidemiology 14 (2022)
Xiaoye Li, Chengchun Zuo, Qiuyi Ji, Ying Xue, Zi Wang, Qianzhou Lv
Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study. Drug design, development and therapy 15 (2021)
Qiuyi Ji, Chunyu Zhang, Qing Xu, Zi Wang, Xiaoye Li, Qianzhou Lv
The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. British journal of clinical pharmacology 87 (5) (2020)